Clinical trial · Observational
Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 9, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260909-000002
Summary
Brief summary (as posted)
This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neuroendocrine Carcinoma | Lung Neuroendocrine Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Neuroendocrine Carcinomas | Neuroendocrine Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients with extra-pulmonary neuroendocrine carcinoma
- description
- Patients with Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), diagnosed between August 2014 and August 2024.
- interventionNames
- Other: Observational study
- label
- Patients with pulmonary neuroendocrine carcinoma
- description
- Patients with Large-cell neuroendocrine carcinoma (LCNEC) or mixed and patients with Small Cell Lung Cancer (SCLC) or mixed, diagnosed between August 2014 and August 2024.
- interventionNames
- Other: Observational study
Primary outcomes (6)
- measure
- Patterns of Initial Cancer Treatment: number of participants treated within vs. outside high-volume sites and associated treatment characteristics
- timeFrame
- Throughout the study period, an average of 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥18 years old * Diagnosed between August 2014 and August 2024 with one of the following: * Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) * Large-cell neuroendocrine carcinoma (LCNEC) or mixed * Small Cell Lung Cancer (SCLC) or mixed * Adequate and accessible medical records for data collection * Tumor block collected from 2014 onwards Exclusion Criteria: * Patients with active, concurrent malignancies at the time of NEC diagnosis, except for non-invasive cancers like basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer. * Patients or their legal representatives unwilling or unable to provide informed consent (if needed per ethics committee).
References
Publications (0)
Data not yet available